Skip to main content
. 2020 Apr 9;15(4):e0231446. doi: 10.1371/journal.pone.0231446

Fig 3. Performance on validation set 2.

Fig 3

a) DRS for the validation set 2 using BESC, SVA, RUV and HCP and the permuted null BES b) Contribution of variance due to disease status, calculated using PVCA c) Number of genes differentially expressed between MSI and MSS samples at various levels of correction by BESC, SVA, RUV and HCP.